Differences in FKBP51 regulation following chronic social defeat stress correlate with individual stress sensitivity: Influence of paroxetine treatment

Neuropsychopharmacology

Volumn 37, Issue 13, 2012, Pages 2797-2808

  Wagner, Klaus V ^a   Marinescu, Daria ^a   Hartmann, Jakob ^a   Wang, Xiao Dong ^a   Labermaier, Christiana ^a   Scharf, Sebastian H ^a   Liebl, Claudia ^a   Uhr, Manfred ^a   Holsboer, Florian ^a   Müller, Marianne B ^a   Schmidt, Mathias V ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

antidepressants; chronic stress; depression; FKBP51; HPA axis; resilience

Indexed keywords

CORTICOSTERONE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 51; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; PAROXETINE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION PROFILING; HIPPOCAMPUS; MALE; MENTAL STRESS; MOUSE; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOPHARMACOTHERAPY; THYMUS; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; MALE; MICE; MICE, INBRED C57BL; PAROXETINE; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL; TACROLIMUS BINDING PROTEINS; TREATMENT OUTCOME;

EID: 84869089159     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.150     Document Type: Article

References (51)

1. Bartolomucci A, Palanza P, Sacerdote P, Panerai AE, Sgoifo A, Dantzer R et al (2005). Social factors and individual vulnerability to chronic stress exposure. Neurosci Biobehav Rev 29: 67-81.
2. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868.
3. Berton O, Nestler EJ (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7: 137-151.
4. Binder EB (2009). The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34(Suppl 1): S186-S195.
5. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B et al (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319-1325.
6. Blokland A, Ten Oever S, van Gorp D, van Draanen M, Schmidt T, Nguyen E et al (2012). The use of a test battery assessing affective behavior in rats: order effects. Behav Brain Res 228: 16-21.
7. Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE (2004). The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 55: 1171-1178.
8. Carvalho LA, Pariante CM (2008). In vitro modulation of the glucocorticoid receptor by antidepressants. Stress 11: 411-424.
9. Choleris E, Thomas AW, Kavaliers M, Prato FS (2001). A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. Neurosci Biobehav Rev 25: 235-260.
10. Chourbaji S, Brandwein C, Vogt MA, Dormann C, Gass P (2008). Evaluation of effects of previous exposure to an acute stressor before testing for depression-like behaviours in mice. Stress 11: 170-175.
11. Chrousos GP (2009). Stress and disorders of the stress system. Nat Rev Endocrinol 5: 374-381.
12. de Kloet ER, Joëls M, Holsboer F (2005). Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6: 463-475.
13. Gupta RK (2009). Major depression: an illness with objective physical signs. World J Biol Psychiatry 10: 196-201.
14. Hartmann J, Wagner KV, Liebl C, Scharf SH, Wang XD, Wolf M et al (2012). The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 62: 332-339.
15. Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG, Kloiber S et al (2008). Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci 28: 389-398.
16. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455: 894-902.
17. Kurt M, Arik AC, Celik S (2000). The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J Basic Clin Physiol Pharmacol 11: 173-180.
18. Linthorst ACE, Reul JM (2008). Stress and the brain: solving the puzzle using microdialysis. Pharmacol Biochem Behav 90: 163-173.
19. Malkesman O, Scattoni ML, Paredes D, Tragon T, Pearson B, Shaltiel G et al (2010). The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry 67: 864-871.
20. McEwen BS (2004). Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann NY Acad Sci 1032: 1-7.
21. McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R (2001). The use of behavioral test batteries: effects of training history. Physiol Behav 73: 705-717.
22. Menke A, Arloth J, Pütz B, Weber P, Klengel T, Mehta D et al (2012). Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 37: 1455-1464.
23. Mizoguchi K, Ishige A, Aburada M, Tabira T (2003). Chronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus. Neuroscience 119: 887-897.
24. Norcross M, Mathur P, Poonam M, Enoch AJ, Karlsson RM, Brigman JL et al (2008). Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice. Psychopharmacology (Berl) 200: 413-424.
25. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404.
26. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW (2004). Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29: 423-447.
27. Petit-Demouliere B, Chenu F, Bourin M (2005). Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 177: 245-255.
28. Pratt WB, Morishima Y, Murphy M, Harrell M (2006). Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 172: 111-138.
29. Reul JM, Stec I, Söder M, Holsboer F (1993). Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133: 312-320.
30. Roy A, Hodgkinson CA, Deluca V, Goldman D, Enoch MA (2012). Two HPA axis genes, CRHBP and FKBP5, interact with childhood trauma to increase the risk for suicidal behavior. J Psychiatr Res 46: 72-79.
31. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917.
32. Sarapas C, Cai G, Bierer LM, Golier JA, Galea S, Ising M et al (2011). Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. Dis Markers 30: 101-110.
33. Savignac HM, Finger BC, Pizzo RC, O'Leary OF, Dinan TG, Cryan JF (2011). Increased sensitivity to the effects of chronic social defeat stress in an innately anxious mouse strain. Neuroscience 192: 524-536.
34. Scharf SH, Liebl C, Binder EB, Schmidt MV, Müller MB (2011). Expression and regulation of the Fkbp5 gene in the adult mouse brain. PloS One 6: e16883.
35. Schmidt MV, Sterlemann V, Ganea K, Liebl C, Alam S, Harbich D et al (2007). Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrinology 32: 417-429.
36. Schmidt MV, Trümbach D, Weber P, Wagner K, Scharf SH, Liebl C et al (2010). Individual stress vulnerability is predicted by shortterm memory and AMPA receptor subunit ratio in the hippocampus. J Neurosci 30: 16949-16958.
37. Sillaber I, Panhuysen M, Henniger MSH, Ohl F, Kühne C, Pütz B et al (2008). Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 200: 557-572.
38. Tennant C (2001). Work-related stress and depressive disorders. J Psychosom Res 51: 697-704.
39. Thase ME (2006). Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr 11: 12-21.
40. Thoeringer CK, Erhardt A, Sillaber I, Müller MB, Ohl F, Holsboer F et al (2010). Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice. J Psychopharmacol (Oxford) 24: 733-743.
41. Touma C, Gassen NC, Herrmann L, Cheung-Flynn J, Büll DR, Ionescu IA et al (2011). FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry 70: 928-936.
42. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9: 519-525.
43. Ulrich-Lai YM, Herman JP (2009). Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 10: 397-409.
44. Venzala E, García-García L, Elizalde N, Delagrange P, Tordera RM (2012). Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors. Psychopharmacology (Berl); e-pub ahead of print, doi:10.1007/s00213-012-2754-5.
45. Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul- Offers SC, Jansen M (2003). Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metab 88: 277-284.
46. Wagner KV, Wang XD, Liebl C, Scharf SH, Müller MB, Schmidt MV (2011). Pituitary glucocorticoid receptor deletion reduces vulnerability to chronic stress. Psychoneuroendocrinology 36: 579-587.
47. Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR (2004). Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci USA 101: 15603-15608.
48. Wang XD, Chen Y, Wolf M, Wagner KV, Liebl C, Scharf SH et al (2011). Forebrain CRHR1 deficiency attenuates chronic stressinduced cognitive deficits and dendritic remodeling. Neurobiol Dis 42: 300-310.
49. Wochnik GM, Rüegg J, Abel GA, Schmidt U, Holsboer F, Rein T (2005). FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem 280: 4609-4616.
50. Wulsin AC, Herman JP, Solomon MB (2010). Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 35: 1100-1112.
51. Zimmermann P, Brückl T, Nocon A, Pfister H, Binder EB, Uhr M et al (2011). Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry 168: 1107-1116.